How to Help Your Patients Find Relpax in Stock: A Provider's Guide

Migraine patients who rely on eletriptan (Relpax) as their acute rescue therapy may be increasingly coming to you with a frustrating problem: they can't find it at their pharmacy. While the FDA has not declared a formal shortage, real-world access issues are creating unnecessary gaps in treatment.

This guide gives you practical, actionable steps to help your patients navigate these issues — from how you write the prescription to the resources you can hand them at checkout.

Step 1: Always Prescribe Generic Eletriptan, Not Brand Relpax

This is the single most important prescribing change you can make. Brand-name Relpax is excluded from most major commercial formularies in 2026 — meaning patients would pay full retail price ($475–$575 for 6 tablets). Generic eletriptan hydrobromide is covered on Tier 1–2 on most plans, available at pharmacies for $24–$25 with a coupon, and more widely stocked.

Write prescriptions as: "Eletriptan hydrobromide 40mg tablets, #9, substitution permitted." Do not mark DAW (Dispense As Written) unless the patient specifically requests brand and can pay cash.

Step 2: Respect Quantity Limits — But Know When to Push Back

Most plans limit triptans to 6–9 tablets per 30-day fill. For patients with episodic migraine occurring 4–8 days per month, this is likely adequate. However, if a patient has high-frequency migraines or uses eletriptan for both acute and early-symptom treatment, you may need to:

Document the clinical rationale for quantities exceeding plan limits in your notes

Consider adding a CGRP preventive therapy (erenumab, fremanezumab, galcanezumab, or oral rimegepant) to reduce acute medication days

Submit a prior authorization or quantity limit exception if clinically justified

Step 3: Recommend Independent Pharmacies to Your Patients

One of the most effective things you can tell your patient is: "Try an independent pharmacy." Unlike large chains that rely on centralized purchasing algorithms, independent pharmacists make their own stocking decisions and are far more likely to special-order medications like eletriptan within 24 hours.

If you have a preferred independent pharmacy in your area that you've found reliable for specialty or lower-volume medications, share that recommendation with patients.

Step 4: Direct Patients to medfinder.com

Consider adding medfinder.com to your patient handout materials. medfinder for providers is a service that calls pharmacies near your patient to check which ones have their medication in stock. The patient enters their medication name, dose, and location — and gets results texted to them. It saves patients the frustration of calling pharmacy after pharmacy during a migraine episode.

Step 5: Counsel Patients to Refill Early

Since eletriptan is an as-needed medication, patients tend to fill it reactively — often calling in a refill right as they take their last tablet. Counsel your migraine patients to refill when they have 1–2 tablets remaining. Most insurance plans allow refill when 75% of the previous supply has been used.

Step 6: Have a Bridge Prescription Protocol

When a patient is out of eletriptan and cannot locate it nearby, having a standing bridge protocol saves them an unnecessary office visit:

For most patients: rizatriptan 10mg or sumatriptan 100mg as a 3–6 tablet bridge (most pharmacies stock these reliably)

For patients with CV contraindications: ubrogepant 50mg or rimegepant 75mg (requires prior auth on most plans)

For patients with severe nausea: consider sumatriptan nasal spray or injectable

Key Messages to Share With Patients at Checkout

"Ask for generic eletriptan, not just Relpax — it's the same drug and more widely stocked."

"Try medfinder.com if your pharmacy is out — they'll find it for you."

"Refill when you have 1–2 tablets left, not when you're completely out."

"If you use a GoodRx or SingleCare coupon, generic eletriptan can cost as little as $24–$25 for 6 tablets."

For a broader overview of the eletriptan availability landscape, see our article on what providers need to know about the Relpax situation in 2026.